Comparison of Intravenous Labetalol and Oral Nifedipine in Acute Control of Severe Hypertension Pregnancy

Background Globally, hypertensive diseases account for 14% of maternal fatalities. The risk of maternal death increases when blood pressure is more than 160/110 mmHg. Method This prospective, randomized clinical trial was carried out with participation from the JJM Medical College, Bapuji Hospital, Chigateri General Hospital, and Women and Child Health Hospital, all of which are connected with Davanagere. Result This study contained 100 cases in total; the subjects were split into two groups according to the medications they received. Patients in groups A (labetalol) and B (nifedipine) had average ages of 24.47 and 23.07 years, respectively. 46% of the women in the labetalol group were primigravida, and 54% were multigravida; 38% of the women in the nifedipine group were primigravida, and 62% were multigravida. The average number of doses required to reach the desired blood pressure was 2.86 with labetalol and 1.66 with nifedipine. Conclusion According to our ndings, oral nifedipine is a better option—especially in low-resource settings—than intravenous labetalol for treating acute severe hypertension in pregnancy. It is also more cost-effective.